Humana Inc. $HUM Stock Sold by Sivik Global Healthcare LLC

Sivik Global Healthcare LLC decreased its holdings in Humana Inc. (NYSE:HUM) by 11.5% during the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 17,700 shares of the insurance provider’s stock after selling 2,300 shares during the period. Humana comprises 4.2% of Sivik Global Healthcare LLC’s portfolio, making the stock its 2nd largest holding. Sivik Global Healthcare LLC’s holdings in Humana were worth $6,754,000 as of its most recent SEC filing.

A number of other hedge funds have also made changes to their positions in HUM. Manning & Napier Advisors LLC bought a new position in shares of Humana during the 2nd quarter worth about $1,412,000. The Manufacturers Life Insurance Company raised its position in shares of Humana by 10.5% during the second quarter. The Manufacturers Life Insurance Company now owns 70,185 shares of the insurance provider’s stock valued at $27,879,000 after buying an additional 6,690 shares during the last quarter. Vista Investment Partners LLC bought a new stake in shares of Humana in the third quarter valued at about $3,254,000. Pzena Investment Management LLC bought a new stake in shares of Humana in the second quarter valued at about $1,749,014,000. Finally, Ameritas Advisory Services LLC acquired a new stake in Humana during the second quarter worth about $1,709,000. 92.38% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

Several equities analysts recently issued reports on HUM shares. Royal Bank Of Canada boosted their price target on Humana from $246.00 to $415.00 and gave the company a “sector perform” rating in a research note on Thursday, July 9th. TD Cowen raised their price objective on Humana from $350.00 to $370.00 and gave the stock a “hold” rating in a research report on Friday, July 31st. Evercore raised Humana from an “in-line” rating to an “outperform” rating and set a $480.00 price objective on the stock in a report on Wednesday, July 29th. UBS Group lifted their price objective on Humana from $405.00 to $495.00 and gave the stock a “neutral” rating in a report on Monday. Finally, Piper Sandler upgraded Humana from a “hold” rating to an “overweight” rating and set a $463.00 price objective on the stock in a research report on Thursday, July 30th. Twenty-one analysts have rated the stock with a Buy rating, ten have issued a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $453.30.

Humana News Roundup

Here are the key news stories impacting Humana this week:

• Positive Sentiment: BlackRock joint venture strengthens CenterWell strategy: Humana announced a new venture with funds managed by BlackRock to operate nearly 150 CenterWell Senior Primary Care clinics. BlackRock will hold a majority stake, while CenterWell will retain a minority interest, potentially providing Humana with additional capital and an asset-light operating structure. Humana Announces New Strategic Joint Venture with BlackRock
• Positive Sentiment: Analysts raised their valuation outlook: Mizuho increased its price target to $495 from $468 and maintained an outperform rating. Raymond James also upgraded Humana to outperform with a $520 target, supporting the bullish case for a recovery in Medicare Advantage profitability.
• Positive Sentiment: Medicare Advantage quality ratings improved: Humana said 95% of its members are enrolled in plans rated four stars or better for 2027. Higher ratings could support future quality bonuses, including potentially larger 2028 payments, and improve the competitiveness of Humana’s plan offerings. Humana Hits 95% Four-Star Coverage
• Positive Sentiment: Sector sentiment improved: UnitedHealth’s earnings beat and raised outlook lifted several managed-care stocks, including Humana, suggesting investors may be responding favorably to improving industry fundamentals.
• Neutral Sentiment: Unusual call-option activity: Traders purchased 8,702 Humana call options, 43% above average daily volume. This indicates increased speculative interest but does not guarantee sustained buying in the shares.
• Neutral Sentiment: Next earnings date set: Humana will report third-quarter 2026 results on November 6. The approaching release may encourage caution as investors await updated medical-cost trends and full-year guidance. Humana to Release Third Quarter 2026 Results
• Negative Sentiment: Valuation and execution concerns remain: After a substantial recent advance, investors may be taking profits and demanding evidence that improved Medicare Advantage ratings and the CenterWell venture will translate into stronger earnings. The company’s relatively elevated valuation increases sensitivity to any disappointing guidance or medical-cost developments.

Humana Price Performance

Shares of Humana stock traded down $7.81 during trading on Tuesday, hitting $425.69. 1,170,547 shares of the company’s stock traded hands, compared to its average volume of 1,664,688. The company has a market cap of $51.12 billion, a PE ratio of 40.21, a PEG ratio of 2.67 and a beta of 0.74. The firm’s fifty day moving average price is $389.75 and its 200 day moving average price is $336.54. Humana Inc. has a twelve month low of $163.11 and a twelve month high of $456.50. The company has a debt-to-equity ratio of 0.62, a current ratio of 1.74 and a quick ratio of 1.74.

Humana (NYSE:HUM) last posted its quarterly earnings results on Wednesday, July 29th. The insurance provider reported $7.61 earnings per share (EPS) for the quarter, topping the consensus estimate of $7.27 by $0.34. The firm had revenue of $40.89 billion during the quarter, compared to analyst estimates of $40.58 billion. Humana had a net margin of 0.88% and a return on equity of 11.20%. The company’s quarterly revenue was up 26.2% compared to the same quarter last year. During the same quarter in the prior year, the business posted $6.27 earnings per share. Analysts forecast that Humana Inc. will post 9.00 earnings per share for the current year.

Humana Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Friday, November 27th. Stockholders of record on Friday, October 30th will be paid a $0.8850 dividend. This represents a $3.54 annualized dividend and a dividend yield of 0.8%. The ex-dividend date is Friday, October 30th. Humana’s dividend payout ratio is currently 33.49%.

About Humana

Humana Inc is a health and well-being company headquartered in Louisville, Kentucky. Founded in 1961, the company began as a nursing home operator before expanding into hospitals and health insurance. Today, Humana primarily provides health insurance products and healthcare services for older adults, individuals, military families and other members in the United States.

Humana’s insurance business offers Medicare Advantage, Medicare Supplement and prescription drug plans, as well as Medicaid coverage in select markets.